Skip to main content
BDRX
NASDAQ Life Sciences

Biodexa Pharmaceuticals Appoints Fiona Sharp as New CFO and Director

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$2.4
Mkt Cap
$1.518M
52W Low
$2.22
52W High
$92
52W Position info
8.1% above low
Off High info
97% below high
Rel. Volume
Market data snapshot near publication time

BDRX is trading near its 52-week low of $2.22 (8.1% above the low).

Summary

Biodexa Pharmaceuticals Plc appointed Fiona Sharp, its former Group Financial Controller, as Chief Financial Officer and a Director, allowing CEO Stephen Stamp to focus on his primary role.


Key Events · Executive and Board Changes · BDRX

  • New Chief Financial Officer Appointed

    Fiona Sharp, previously the Group Financial Controller, has been appointed as Chief Financial Officer and Corporate Secretary, effective January 5, 2026.

  • Board Appointment

    Ms. Sharp will also join the Board of Directors, serving until the Company's annual general meeting in 2026.

  • CEO Focuses on Core Role

    Stephen Stamp has relinquished his CFO and Corporate Secretary positions to focus exclusively on his role as Chief Executive Officer.


Analysis · BDRX · Life Sciences

Biodexa Pharmaceuticals Plc has strengthened its executive leadership by appointing Fiona Sharp, previously the Group Financial Controller, as Chief Financial Officer and a member of the Board of Directors. This move allows Stephen Stamp to focus solely on his role as Chief Executive Officer, enhancing management specialization. Ms. Sharp's internal experience and background as a Chartered Certified Accountant are crucial for financial oversight and strategic planning, particularly for a company of Biodexa's size.

How filings like this one have moved

In the 30 days to Sep 11, 2026, 30.5% of the 1996 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.21%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, BDRX was trading at $2.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5M. The 52-week trading range was $2.22 to $92.00. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

BDRX - Latest Insights

BDRX
Aug 19, 2026, 8:30 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $1.45
Real-time Price: $0.687 info
Change: -$0.763 (-53%) info
Market Cap: $835.807K info
BDRX
Aug 04, 2026, 7:53 PM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $1.54
Real-time Price: $0.687 info
Change: -$0.853 (-55%) info
Market Cap: $835.807K info
BDRX
Aug 04, 2026, 7:00 AM EDT
Filing Type: 424B3
Importance Score:
9
Price at Filing: $1.42
Real-time Price: $0.687 info
Change: -$0.733 (-52%) info
Market Cap: $835.807K info
BDRX
Jul 30, 2026, 6:01 AM EDT
Filing Type: F-1/A
Importance Score:
9
Price at Filing: $1.44
Real-time Price: $0.687 info
Change: -$0.753 (-52%) info
Market Cap: $835.807K info
BDRX
Jul 29, 2026, 4:43 PM EDT
Filing Type: 6-K
Importance Score:
9
Price at Filing: $1.53
Real-time Price: $0.687 info
Change: -$0.8478 (-55%) info
Market Cap: $835.807K info